BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2020 7:36:12 AM | Browse: 623 | Download: 1279
 |
Received |
|
2020-08-03 22:25 |
|
Peer-Review Started |
|
2020-08-03 22:25 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-12 06:22 |
|
Revised |
|
2020-09-30 13:56 |
|
Second Decision |
|
2020-10-19 08:24 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-10-20 04:17 |
|
Articles in Press |
|
2020-10-20 04:17 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-11-02 03:18 |
|
Publish the Manuscript Online |
|
2020-11-06 07:36 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Efficacy and safety of anti-hepatic fibrosis drugs
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Konstantinos Damiris, Zaid H Tafesh and Nikolaos Pyrsopoulos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nikolaos Pyrsopoulos, FACP, MD, PhD, Director, Doctor, Professor, Medicine-Gastroenterology and Hepatology, Rutgers-New Jersey Medical School, 185 S. Orange Avenue, MSB H-535, Newark, NJ 07103, United States. pyrsopni@njms.rutgers.edu |
| Key Words |
Liver; Fibrosis; Cirrhosis; Antifibrotic; Pharmacotherapy; Clinical trial |
| Core Tip |
A number of clinical trials have targeted various etiologies of liver fibrosis and cirrhosis. Some have been promising, particularly in metabolic associated fatty liver disease and viral hepatitis. Results from these studies have shown that there are safe treatments available, forming currently practiced therapeutic guidelines, and shining light on the potential reversibility of liver fibrosis and cirrhosis caused by a variety of etiologies. |
| Publish Date |
2020-11-06 07:36 |
| Citation |
Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i41/6304.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i41.6304 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
